Drug Trial Radar · NCT07678775
Open-Label Extension Study of BBP-418 (Ribitol) for LGMD2I/R9
Last checked: Nov 19, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
107
Planned (sponsor's estimate)
Start
Jun 5, 2026
Primary completion
Oct 2030
Study completion Oct 2030
Sponsor
- Lead sponsor
- ML Bio Solutions, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 1, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label extension (rollover) study designed to evaluate the long-term safety and efficacy of BBP-418 (ribitol) in participants with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) who have previously participated in Study MLB-01-005 (Fortify). Participants will receive BBP-418 administered orally at protocol-defined doses and schedules. The study will assess long-term safety through monitoring of adverse events, clinical laboratory evaluations, and other safety assessments. Efficacy will be evaluated using functional measures and other clinical endpoints relevant to LGMD2I/R9. Participants will be followed for up to 36 months, with a final safety follow-up assessment conducted approximately 30 days after the last dose of study drug.
Conditions
- Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)
Interventions
BBP-418 (ribitol)Drug
Drug: BBP-418. Single arm. Participants who completed Study MLB-01-005 and meet eligibility criteria will receive BBP-418 (ribitol) taken orally twice daily at 9 or 12g (based on body weight measured) for up to 36 months.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency and severity of treatment-emergent adverse events to assess long-term safety of BBP-418.Time frame: 36 months
- Change from baseline in North Star Assessment for LGMD2I/R9 to assess long-term efficacy of BBP-418.Time frame: 36 months
Locations
20 sites in 8 countries. Site status is shown where the registry gives one.
Arkansas Children's Hospital
Little Rock, Arkansas
University of California Irvine Medical Center
Orange, California
University of Colorado Hospital (UCH) - Anschutz Medical Campus
Aurora, Colorado
University of Florida Health Center for Pediatric Neuromuscular and Rare Diseases
Gainesville, Florida
University of Iowa Stead Family Children's Hospital
Iowa City, Iowa
University of Kansas Medical Center (KUMC)
Kansas City, Kansas
Kennedy Krieger Institute
Baltimore, Maryland
University of Minnesota Medical School
Minneapolis, Minnesota
Washington University School of Medicine
St Louis, Missouri
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania
Children's Hospital of the Kings Daughters
Norfolk, Virginia
Royal Brisbane and Women's Hospital
Brisbane, Australia
Rigshospitalet, Neuromuscular Clinic and Research Unit
Copenhagen, Denmark
Charité Universitätsmedizin Berlin and Max Delbrück Center
Berlin, Germany
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
Milan, Italy
Leids Universitair Medisch Centrum
Leiden, Netherlands
Universitetssykehuset Nord-Norge, Department of Neurology
Tromsø, Norway
UCL Great Ormond Street Hospital
London, United Kingdom
Newcastle University - John Walton Muscular Dystrophy Research Centre
Newcastle upon Tyne, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.